Shares of Cannabis Science Inc. (OTC: CBIS), a developer of pharmaceutical grade medical cannabis products, have risen sharply in trading today.
At last check, CBIS shares were trading 17.50% higher at $0.0705 on above average volume of 8.85 million. The stock has gained more than 35% in the last three trading sessions.
CBIS this week announced that it initiated a research program to explore the commercial development of Phytocannabinoid-based therapeutics for drug resistant HIV infection. Dr. Robert Melamede, CEO of Cannabis Science, said that CBIS is dedicated to the development of the first Phytocannabinoid-based treatment for HIV and the company’s program is based on the initial identification of antiviral activity of Phytocannabinoids against TAT activity.
Cannabis Science also announced the appointment of Roscoe Moore, DVM, Ph. D., MPH, to its Scientific Advisory Board. Dr. Moore has served as the chief epidemiologist with the Centers of Devices and Radiological Health in the U.S. FDA. He has also held positions in the U.S. Public Health Service.
Recent Comments